Cancer Cell Therapy

Non-Hodgkins Lymphoma

≥ 18 Yrs

Diffused Large B-Cell Lymphoma

Relapsed or refractory disease third-line

Will replace CCT5024 after it opens

Relapsed or refractory disease after CD19-directed therapy

CCT5029
Phase I/II
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

PI: Muffy Stanford

CCT5041
Phase I
Anti-CD70 CRISPR-Cas9-Engineered TCells(CTX130) in Relapsed/Refractory T/B Cell Malignancies

PI: Weng CRISPR

CCT5016
Managed Access Program (MAP)
CTLO19 in ALL or DLBCL

PI: Miklos Sponsor: Novartis

CCT5001
Phase I
CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Recurrent/Refractory B Cell Malignancies

PI: Miklos Stanford

Priority: 1st

CCT5024
Phase II
ALL-501/Allogeneic CAR TCell Tx in Relapsed/Refractory Large B-Cell & Follicular Lymphoma

PI: Miklos Allogene

Priority: 2nd

CCT5022
Phase II
Axicabtagene Ciloleucel +/- Rituximab or Lenalidomide in Refractory Large B-Cell Lymphoma

PI: Parveen Sponsor: Kite Pharma

Priority: 3rd

CCT5036
Phase II
Lenzilumab &Axicabtagene Ciloleucel in Relapsed/Refractory Large B-cell Lymphoma

PI: Parveen Sponsor: Kite Pharma

CCT5043
Phase I/II
ALLO-501A Anti-CD19 Allogeneic CAR T-Cell Tx in Relapsed/Refractory Large B-Cell Lymphoma

PI: Miklos Sponsor: Allogene

Priority: 3rd

KEY

- Pending
- Open for Enrollment
- Optional Path
- Link
- Trial Posting
- Extension Study
- Immunothetaapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu